Morgan Stanley has downgraded Regeneron Pharmaceuticals Inc (REGN) to Equal-Weight from Overweight, a decision announced on December 2, 2025. The current share price stands at $726.00.
This downgrade indicates a more cautious outlook for Regeneron, reflecting potential concerns over competitive pressures, market conditions, or execution risks that could affect the company's performance. Regeneron, based in Tarrytown, New York, is a biotechnology firm that focuses on developing and commercializing medicines for serious diseases. The company employs 15,106 full-time staff and boasts a market capitalisation of $78.8 billion, with a P/E ratio of 17.22 and an EPS of 41.78.
Upcoming earnings reports are anticipated on July 30, 2026, with an estimated EPS of $11.68 and revenue of $3.8 billion, following a strong performance in Q3 2025 where the EPS exceeded estimates by 21%. Analyst consensus remains generally positive, with 10 Strong Buy, 17 Buy, 8 Hold, 1 Sell, and no Strong Sell ratings as of December 1, 2025.
Analyst ratings represent professional opinions based on detailed research and financial models. While they can offer valuable insights, these assessments are built on assumptions that may not always hold true. Investors are advised to consider a range of factors, including company fundamentals and market trends, when making financial decisions. Analyst ratings can change as new information emerges, leading to varied opinions on the same company.